Skip to main content
Premium Trial:

Request an Annual Quote

Underwriters Exercise Option to Purchase Additional Sequenom Shares

NEW YORK (GenomeWeb News) – Sequenom said today that the underwriters of its recently completed public offering of common stock have exercised an option to acquire an additional 825,000 shares.
 
Last week, the firm offered 5.5 million shares of common stock at $15.50 per share.
 
The exercise of the over-allotment option brings the total number of shares sold to 6,325,000 and net proceeds to $92 million.
 
Sequenom intends to use the funds to develop diagnostic tests for use on its MassArray system and other platforms, as well as for general corporate purposes. The firm also said it may use the proceeds to acquire or invest in other businesses.
 
The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.